At baseline, urinary biomarker analysis showed that clinical BPH patients had significantly higher levels of TAC, prostaglandin E2 (PGE2), IL-1β, and IL-6 compared to controls (Table 2). This evidence concerns the gene IL6 and benign prostatic hyperplasia.